Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.
Latest from Jessica Merrill
Vertex, Bristol Myers and Regeneron updated investors on launches underway, while Sanofi CEO Paul Hudson assured investors on the late-stage pipeline.
AstraZeneca, Lilly, Novo Nordisk and Amgen all moved up in the rankings on the Scrip 100 leaderboard powered by impressive double-digit growth.
The pivotal Phase III trial met the primary and secondary endpoints, showing skeletal and cardiac benefits and supporting deramiocel as a treatment for Duchenne cardiomyopathy.
The Trump administration leveraged tariffs to convince the UK National Health Service to increase prices for new medicines by 25%.
Leadership, organizational excellence and good old fashioned customer engagement could hold keys to better aligning across go-to-market groups, commercial leaders say.
Redemplo is Arrowhead’s first commercial product, and the drug will enter a competitive market. Arrowhead and Ionis have taken different pricing paths, however.